biote Corp. (BTMD)

Nasdaq Pharmaceutical Pharmaceutical Chemicals SIC: 2833
D
Pipeline Grade

Financial Position (from SEC Filings)

$5.3M
Cash & Equivalents
$3.9M
Quarterly Burn Rate
$75M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

No upcoming catalysts detected for this company.

Active Clinical Trials (1)

NCT #TitlePhaseStatusEnrollment
NCT06348264 Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive, High-risk Salivar... PHASE2 Recruiting 37

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for BTMD.

SEC EDGAR Filings

All SEC filings for biote Corp. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.